NTRK1 and astrocytoma (excluding glioblastoma): Today, still very limited data is published about the clinical use of inhibitors targeting these receptor tyrosine kinases (RTKs) in pediatric brain tumors, and even less is known in low grade astrocytoma and ependymoma.